MDR-104

N/A

Report date: 2024/11/21 16:07:27

Base Information

Drug NameMDR-104
Drug Alias NameMDR-104
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHematopoietic progenitor cell antigen CD34 modulatorsT cell surface glycoprotein CD3 modulators
TargetsHematopoietic progenitor cell antigen CD34T cell surface glycoprotein CD3
Therapy Area/IndicationsRejection of renal transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedeor Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMedeor Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A